BioNexus Gene Lab (BGLC) Liabilities and Shareholders Equity (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 4.64% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $35.3 million (down 15.97% YoY), and the FY2025 full-year result was $9.3 million, down 11.32% from the prior year.
• Liabilities and Shareholders Equity eased to $9.0 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.5 million in Q3 2023 to a low of $7.6 million in Q3 2025.
• A 5-year average of $9.5 million and a median of $9.3 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 47.03% in 2023 and slumped 30.68% in 2025, its largest moves.
• Tracing BGLC's Liabilities and Shareholders Equity over 5 years: stood at $8.7 million in 2022, then soared by 30.43% to $11.4 million in 2023, then slipped by 8.47% to $10.4 million in 2024, then slipped by 11.32% to $9.3 million in 2025, then slipped by 2.3% to $9.0 million in 2026.
• Business Quant data shows BGLC's Liabilities and Shareholders Equity at $9.0 million in Q1 2026, $9.3 million in Q4 2025, and $7.6 million in Q3 2025.